1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Guilin Sanjin Pharmaceutical Co., Ltd.

Guilin Sanjin Pharmaceutical Co., Ltd.

002275.SZ
Guilin Sanjin Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
13.50
CNY
+0.33
- -
7.93BMarket Cap
Guilin Sanjin Pharmaceutical Co., Ltd.
002275.SZ
(Shenzhen Stock Exchange)

Recent

price

13.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.67
1.95
2.22
2.47
2.48
2.36
2.6
2.75
2.68
2.8
2.71
3.04
3.33
3.71
3.74
3.5
3.65
Revenue per Share
0.44
0.49
0.56
0.71
0.75
0.64
0.67
0.79
0.7
0.67
0.48
0.6
0.56
0.72
0.89
0.74
0.87
Basic EPS, GAAP
0.32
0.36
0.16
- -
0.31
0.47
0.8
0.59
0.78
0.41
0.68
0.46
0.79
0.81
0.86
1.06
-0.2
Free Cash Flow per Basic Share
0.43
0.17
0.4
0.5
0.55
0.61
0.5
0.41
0.4
0.36
0.25
0.79
0.97
0.73
0.57
0.58
0.62
Dividend per Share
1.42
1.9
2.03
2.15
2.29
2.23
2.4
2.79
3.07
3.42
3.72
3.55
3.12
3.15
3.49
3.68
3.65
Book Value per Share
2.78
3.06
3.22
3.39
3.62
3.72
3.81
4.21
4.45
4.5
4.81
4.64
4.49
4.54
4.88
5.21
5.13
Tangible Book Value per Share
588
596
591
594
590
588
588
588
590
585
577
573
588
585
586
585
582
Basic Weighted Avg Shares
983
1,162
1,312
1,469
1,466
1,391
1,525
1,616
1,585
1,640
1,566
1,741
1,960
2,172
2,194
2,046
2,124
Sales/Revenue/Turnover
30.43
29.18
29.47
31.9
34.07
28.92
29.51
33.36
31.45
28.45
21.45
23.55
20.84
23.72
26.1
27.77
25.99
Operating Margin (%)
26
27
28
30
35
61
65
69
76
91
80
107
115
115
110
99
- -
Depreciation Expense
259
292
331
422
445
377
394
464
413
392
277
344
330
421
522
433
507
Net Income, GAAP
18.71
20.06
18.5
18.14
16.25
14.46
17.91
17.51
16.61
16.14
19.51
19.89
26.14
18.71
19.01
19.33
19.55
Effective Tax Rate (%)
26.31
25.13
25.25
28.72
30.34
27.07
25.81
28.74
26.08
23.9
17.68
19.74
16.81
19.4
23.77
21.17
23.89
Profit Margin (%)
1,355
1,436
1,411
1,352
1,290
1,233
1,234
1,486
1,642
1,582
1,775
1,625
1,450
1,302
1,569
1,580
1,542
Working Capital
4
3
2
1
- -
- -
- -
- -
- -
75
336
315
206
135
150
207
157
LT Debt
1,800
1,983
2,078
2,211
2,321
2,386
2,426
2,654
2,807
2,815
2,959
2,840
2,813
2,817
3,010
3,191
3,130
Total Equity
13.21
14.15
15.31
17.46
17.82
14.1
14.79
16.58
14.28
13.01
8.29
9.41
8.81
12.42
13.18
12.4
12.2
Return on Invested Capital (%)
30
29.4
28.52
33.76
33.01
27.4
28.04
29.14
22.87
19.34
11.81
13.52
13.94
18.6
21.27
16.93
19.67
Return on Capital (%)
30.65
29.65
28.4
34.07
33.79
28.25
28.93
30.47
23.94
20.54
13.34
16.44
17.04
22.9
26.83
20.63
24.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
443
507
487
LT Borrowings
122
129
126
LT Finance Leases
29
25
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
588
588
588
Market Capitalization
8,878
8,187
8,333

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,565
2,865
2,403
Cash, Cash Equivalents & STI
1,676
1,975
1,660
Accounts Receivable, Net
86
204
244
Inventories
208
223
221
Total Current Liabilities
995
959
861
Payables & Accruals
- -
- -
- -
ST Debt
443
507
487
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.03%
1.61%
6.02%
Free Cash Flow
16.53%
14.84%
22.72%
Net Income, GAAP
3.17%
10.93%
-16.95%
Sales/Revenue/Turnover
4.15%
5.76%
-6.76%
Total Cash Common Dividend
11.13%
38%
1.46%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
483
586
506
619
2,194
2025
467
532
583
- -
2,046
2026
525
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
- -
- -
- -
0.89
2025
0.18
- -
- -
- -
0.74
2026
0.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.57
2025
0.01
- -
- -
- -
0.58
2026
0.01
- -
- -
- -
- -
Similar Companies
SillaJen, Inc. (215600.KQ)
PeptiDream Inc. (4587.T)
Living Cell Technologies Limited (LVCLY)
NewAmsterdam Pharma Company N.V. (NAMS)
Everest Medicines Limited (1952.HK)
Disc Medicine, Inc. (IRON)
Business
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) engages in the research, development, production, and sale of traditional Chinese medicines and natural medicines primarily in China. Founded in 1967 and headquartered at No. 1 Jinxing Road in Guilin, Guangxi Zhuang Autonomous Region, the company operates as a subsidiary of Guilin Sanjin Group Co., Ltd. and maintains manufacturing facilities adhering to Good Manufacturing Practice standards. Its core products include the Sanjin Watermelon Frost series (Guilin Watermelon Frost, Watermelon Frost lozenges, Watermelon Frost throat tablets, and Watermelon Frost throat cleansing tablets) for throat, oral cavity, and dental conditions; Sanjin tablets for urinary tract infections, bladder inflammation, kidney inflammation, and prostate issues; Naomaitai (Naomai) capsules and Naomai tablets (also called Brain Pulse Tai capsules) for vertigo and dizziness; Yuye (Jade Leaf) detoxification granules for colds, coughs, laryngitis, sore throat, and urinary symptoms; Compound Tianqi stomach pain capsules for gastrointestinal discomfort; and additional proprietary Chinese medicine preparations covering respiratory, cardiovascular, and digestive health segments, with over 200 registered varieties and 47 exclusive formulations. The company targets domestic healthcare providers, pharmacies, hospitals, and consumers, with expanding international sales to over 30 countries in Southeast Asia, Europe, and Africa, driven by e-commerce channels accounting for around 30% of sales and partnerships with online platforms. Recent developments include recognition as a "Zhonghua Laozhao" (time-honored brand) in April 2024; Chairman Zou Xun receiving the National Labor Model award in May 2025; multiple marketing awards in 2024 and 2025 for Sanjin tablets and Watermelon Frost products, such as the 31st China International Advertising Festival Gold Case and China Innovation Communication Awards; profit growth in double digits for 2024 reported in April 2025; accelerated construction of the Sanjin Chinese Medicine City production warehouse expansion project as of July 2025; and ongoing R&D investments at approximately 10-12% of revenue, yielding new patents, product launches in oncology and chronic diseases, and clinical trials for innovative compounds through academic collaborations.